Please assess the completion status of the following clinical trial:

Trial Title: Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with mild to moderate, stable chronic plaque psoriasis.~Exclusion Criteria:~* patients with severe psoriasis.~* Patients received any topical or systemic treatment for psoriasis one month before the start of the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ethosomal anthralin (Type: EXPERIMENTAL): Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
- liposomal anthralin (Type: ACTIVE_COMPARATOR): Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).